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Abstract
Background: Salivary duct carcinoma (SDC) is a high-grade salivary gland malignancy that is associated with an
aggressive clinical behavior and poor prognosis. Herein, we report on a long surviving case of SDC of the minor
salivary gland with multiple lymph node metastases (LNMs).
Case presentation: An 83-year-old woman presented with a history of lymphadenopathy in the right side of the
neck and recent onset and rapid growth of a mass in the right buccal region. Clinical examinations and biopsy
findings were suggestive of a salivary gland malignant tumor with regional LNMs. The patient was treated with
neoadjuvant chemotherapy. Tumor excision and ipsilateral radical neck dissection were performed, followed by
adjuvant chemoradiotherapy. Postoperative histological examination revealed a tumor with irregular nests of
atypical ductal epithelial cells, a cribriform growth pattern, and comedo-like central necrosis that lead to a final
diagnosis of SDC. LNMs were observed in six lymph nodes of the right side of the neck. The patient underwent
postoperative chemotherapy using single-agent cisplatin that was administered concurrently with radiotherapy
(total, 65 Gy). There was no evidence of local recurrence or distant metastasis for >6 years.
Conclusions: Although available data on treatment modalities for SDC remain limited, multimodal therapy may
contribute to improved clinical outcomes in patients with advanced intraoral SDC.
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Background
Salivary duct carcinoma (SDC) is a rare malignant tumor
that arises from the ductal epithelial cells of the salivary
glands. SDC was first described by Kleinsasser et al. [1] in
1968 as a highly aggressive, malignant salivary gland
tumor. It was then classified as a distinct entity of salivary
gland tumors by the World Health Organization in 1991
[2]. SDC most frequently arises in the major salivary
glands, especially the parotid glands. However, it can also
occur more infrequently in the minor salivary glands of
the oral cavity [3]. SDC has an aggressive clinical behavior
and poor clinical outcome that is characterized by the
rapid growth of the disease, multiple nodal metastases,
early distant metastasis (DM), and a high rate of recur-
rence [3]. Recently, prognostic factors for SDC have been
extensively studied in large numbers of patients and it has
been suggested that adjuvant therapy may improve the
clinical outcome of patients with advanced SDC [3–8].
However, because the incidence of SDC of minor salivary
gland origin is very low compared to that of SDC of major
salivary gland origin, and a limited number of cases have
been reported to date, the clinical outcome and benefit of
adjuvant therapy for SDC of minor salivary gland origin
remains to be elucidated. Therefore, additional studies are
required to better understand the prognostic factors for
patients with intraoral SDC.
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To the best of our knowledge, we are the first to
report on the treatment outcome of a long surviving
intraoral SDC patient with multiple lymph node metas-
tases (LNMs).
Case presentation
An 83-year-old woman, complaining of an asymptomatic
painless swelling in the right buccal region, was referred
to our department in 2009. The lesion had not been long
standing and had recently gradually increased in size. Ini-
tially, the patient was seen by a general dental practitioner,
when she had first noticed the lesion, and was subse-
quently referred to the Department of Oral and Maxillo-
facial Surgery at a local hospital where a diagnosis of a
neoplasm of the buccal region was suggested. She was
then referred to our department. The patient had a med-
ical history of myocardial infarction that was treated with
coronary artery stenting at the age of 76 years. On initial
assessment, no systemic symptoms were evident. Extraoral
and intraoral examination revealed a lesion in the right
buccal region, measuring 2.0 × 1.8 cm, that was palpable,
indurated, and elastically hard without trismus (Fig. 1a).
The overlying mucosa was partially ulcerated. Laboratory
examinations revealed no significant findings except for
elevated levels (6.3 ng/mL) of tumor marker serum cyto-
keratin fragment 21.1. Squamous cell carcinoma and car-
cinoembryonic antigen levels were 2.1 and 2.4 ng/mL,
respectively. Computed tomography exhibited homoge-
neous enhancement of an ill-demarcated lesion in the
right buccal region (Fig. 1b). Computed tomography of
the neck detected several enlarged lymph nodes in ipsilat-
eral levels I–III that suggested the presence of LNMs
(Fig. 1c). No other specific findings were observed by
computed tomography of the abdominal or thoracic re-
gions. An intraoral biopsy was performed and histopatho-
logical findings were suggestive of a malignant salivary
gland neoplasm. Accordingly, the tumor in the right buc-
cal region was classified as T4aN2bM0.
Initially, the patient was treated with induction chemo-
therapy using an intra-arterial infusion of high-dose cis-
platin (100 mg/body on day 1) and concurrent peroral
TS-1 (100 mg/body on days 1–14). The tumor size was
reduced from 34.2 to 26.0 mm, with a tumor reduction
rate of 24.0% by computed tomography measurements
Fig. 1 a An intraoral photograph revealing an ulcerated lesion in
the right buccal region. b, c Computed tomography demonstrating
a homogeneously enhanced lesion in the right buccal region and
multiple, enlarged lymph nodes in the right side of the neck. The largest
diameter of the tumor on initial assessment (b) and after induction
chemotherapy (d) was 34.2 to 26.0 cm, respectively. The tumor exhibited
a reduction in size (d) in response to induction chemotherapy using an
intra-arterial infusion of high-dose cisplatin and concurrent peroral TS-1
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(Fig. 1d). Tumor excision using both intraoral and extra-
oral approaches and ipsilateral radical neck dissection
were performed. The surgical defect of the right buccal
region was patched using a split thickness skin graft.
Macroscopically, the tumor measured 2.2 × 2.2 × 1.7 cm.
It had a solid, whitish appearance with muscle layer inva-
sion at the cut surface. The overlying mucosal surface was
partially ulcerated. Microscopically, the lesion was com-
posed of a neoplastic component characterized by atypical
ductal epithelial cells, a cribriform growth pattern, and
comedo-like central necrosis (Fig. 2a, b). The epithelium
was primarily composed of polygonal shaped cells with an
abundant eosinophilic cytoplasm and large nuclei (Fig. 2c).
The tumor was distinct from the parotid gland, suggesting
that it had originated from the minor salivary gland of the
buccal region. Lymphovascular invasion and perineural in-
vasion (PNI) were observed (Fig. 2d–f ). Furthermore,
LNMs were evident in six (level IB [n = 1], IIA [n = 2], and
IIB [n = 3]) of the 25 dissected lymph nodes. Metastatic
lymph nodes exhibited similar histopathology findings as
the primary site of the lesion. The tumor cells stained
positive for androgen receptor, epithelial membrane antigen
(EMA), cytokeratin 7, and gross cystic disease fluid protein-
15 (GCDFP-15) but negative for alpha-smooth muscle actin
(α-SMA), calponin, carcinoembryonic antigen (CEA), cyto-
keratin 14, human epidermal growth factor receptor 2
(HER2)/neu, estrogen receptor, S100 protein, vimentin, and
tumor protein p53 (Fig. 3a–d). The Ki-67 proliferation
index was 36.0%. According to these histopathological fea-
tures, the tumor was diagnosed as a SDC of minor salivary
gland origin. One month after surgery, the patient was
treated with chemotherapy using single-agent cisplatin
(5 mg/m [2]) that was administered concurrently with
radiotherapy (total, 65 Gy) for the primary lesion and ipsi-
lateral neck. The patient has remained alive for >6 years
after the initial diagnosis with no evidence of recurrence.
Discussion
SDC exhibits an aggressive clinical behavior and espe-
cially poor prognosis that is characterized by multiple
nodal metastases, early DM, and a high rate of local
recurrence [3, 4]. According to reports in the literature
Fig. 2 Microscopic features of salivary duct carcinoma on hematoxylin and eosin staining. a, b The tumor was composed of a neoplastic component
characterized by atypical ductal epithelial cells, a cribriform growth pattern, and comedo-like central necrosis. c The epithelium was primarily composed of
polygonal shaped cells with an abundant eosinophilic cytoplasm (numerous mitotic figures) and large nuclei (nuclear atypia). d Lymphatic
invasion, e vascular invasion, and f perineural invasion were observed on podoplanin, elastic Van Gieson, and hematoxylin and eosin staining, respectively
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[3], the rates of nodal metastasis, DM, and local recur-
rence are approximately 60, 50, and 50%, respectively [3].
Moreover, the mean overall survival was 56 months and
the 5-year disease-free survival rates for stage I–IV SDC
were approximately 42, 40, 30, and 23%, respectively [3].
Recently, prognostic factors for SDC have been exten-
sively studied in large numbers of patients and several
factors, including tumor size, anatomical location, age,
positive infiltrative margin, PNI, regional recurrence,
nodal metastasis, and DM have been suggested to be as-
sociated with a poor prognosis [3, 4, 9, 10]. In particular,
it has been suggested that a large tumor size of >3 cm is
associated with a poor prognosis [11], while a small
tumor size of <2 cm is associated with a more favorable
prognosis [9]. However, the prognostic data described
above were established based on the findings of SDC of
major salivary gland origin, owing to the fact that the
majority of SDC cases arise in the major salivary glands,
particularly the parotid glands. Therefore, prognostic
data concerning SDC of minor salivary gland origin re-
mains limited, because the incidence of SDC of minor
salivary gland origin is extremely low compared to that
of SDC of major salivary gland origin. A relatively favor-
able prognosis in patients with SDC of minor salivary
gland origin compared to SDC of parotid gland origin
was suggested based on the finding that the former was
associated with less frequent regional LNMs in a review
of the literature [10, 12]. However, this less aggressive
behavioral tendency of SDC of minor salivary gland ori-
gin is most likely due to the relatively smaller tumor
size, because SDCs of minor salivary gland origin are
detected earlier than SDCs of major salivary gland origin
[10]. There have been no reports describing the differ-
ence in prognosis between patients with SDC of minor
salivary gland origin and patients with SDC of major sal-
ivary gland origin after matching for stage. Histologi-
cally, SDC resembles high-grade ductal carcinoma of the
breast with a solid or cribriform growth pattern. The
majority of immunohistochemical staining investigations
[1–3] have revealed similarities between SDC and breast
carcinoma with positive immunostaining for epithelial
markers such as cytokeratin and epithelial membrane
antigen and particularly intense immunoreactivity for
gross cystic disease fluid protein-15 (GCDFP-15), andro-
gen receptor, and HER2/neu. It has been suggested that
overexpression of HER2/neu and tumor protein p53 are
associated with a poor clinical course, including early
regional recurrences, DM, and low survival rates [3].
Although no consistent therapeutic concept exists for
this entity, complete surgical resection with radical neck
dissection, followed by radiotherapy, has been suggested
as the treatment recommendation for resectable SDC
[13, 14]. Postoperative radiotherapy has been suggested
to improve locoregional control in a patient with ad-
vanced stage SDC [13]. In particular, observations of
PNI during a final pathological examination may lead to
consideration of postoperative radiotherapy [13]. More-
over, only limited data are available regarding the efficacy
of chemotherapeutic agents. Therefore, no consensus ex-
ists for the efficacy of chemotherapy. Molecularly targeted
therapy against HER2 protein with anti-HER2 monoclonal
antibodies has been suggested to be contributive as a
Fig. 3 Immunohistochemical staining for androgen receptor, cytokeratin 7, gross cystic disease fluid protein-15 (GCDFP-15), and human epithelial
growth factor receptor 2 (HER2)/neu. The tumor cells were immunoreactive for a androgen receptor and b cytokeratin 7 and focally immunoreactive
for c GCDFP-15 but were not immunoreactive for (d) HER2/neu
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therapeutic target for patients with HER2/neu-positive
SDC [15, 16]. Anti-androgen therapy has also been evalu-
ated in patients with androgen receptor positive SDC [17].
In the present case, multiple regional LNMs and an
elevated Ki-67 proliferation index were observed. Lym-
phovascular invasion and PNI were also apparent on
histological examination. Therefore, multimodal therapy
with induction chemotherapy, radical surgery, and post-
operative adjuvant chemoradiotherapy was conducted.
In fact, in the present case, induction chemotherapy with
cisplatin led to a 24.0% reduction in tumor size, suggest-
ing that chemotherapy is at least partially effective in
treating patients with SDC. To the best of our know-
ledge, this is the first report describing the efficacy of
multimodal therapy for SDC of minor salivary gland
origin.
Additional studies are required to elucidate further the
clinical outcomes of patients with SDC of minor salivary
gland origin. Particular attention should be paid to the
potential application of multimodal adjuvant therapy,
especially when endeavoring to accumulate adequate ex-
perience of this rare type of tumor. Taking into account
the aggressive clinical behavior of SDC, such as the high
locoregional recurrence rate and early DM, multimodal
therapy should be considered for the management of
this high-grade malignancy.
Conclusions
We present a rare case of SDC of minor salivary gland
origin that was successfully treated with radical surgery
followed by adjuvant chemotherapy and radiotherapy
despite the presence of multiple regional LNMs. Particu-
lar attention was paid to the potential application of
multimodal adjuvant therapy, especially when endeavor-
ing to accumulate adequate experience of this rare type
of tumor.
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